Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Daicel ( (JP:4202) ).
Daicel will book an extraordinary impairment loss of about ¥32 billion in the fourth quarter of the fiscal year ending March 2026, after concluding that a new cyclic olefin copolymer resin plant under construction will be less profitable due to slower demand growth and higher investment costs. The start of operations at this Plant No. 2 will be pushed back from the fourth quarter of fiscal 2027 to within fiscal 2028, with the company planning to use the delay to implement additional safety and quality measures.
In conjunction with the impairment and recent business headwinds, Daicel slashed its full-year forecast for fiscal 2026, trimming sales and operating profit and cutting projected profit attributable to owners of parent from ¥50 billion to ¥10 billion. The downgrade reflects weaker-than-expected sales volumes for acetate and tow amid prolonged customer inventory adjustments, a problem at a carbon monoxide plant, and the postponement to the next fiscal year of relocation compensation tied to an engineering plastics plant in China.
The most recent analyst rating on (JP:4202) stock is a Hold with a Yen1658.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.
More about Daicel
Daicel Corporation is a Japanese chemical manufacturer listed on the Prime Market of the Tokyo Stock Exchange. The company produces advanced materials and specialty chemicals, including cyclic olefin copolymer resins, acetate and tow, serving a range of industrial and engineering plastics markets globally.
Average Trading Volume: 990,201
Technical Sentiment Signal: Buy
Current Market Cap: Yen360.8B
See more insights into 4202 stock on TipRanks’ Stock Analysis page.